However, this anti-PD-1 therapy could fail in clinical settings through the acquisition of other checkpoint inhibitors, and it can be associated with potential risks, like immunosuppression, autoimmunity, etc., that should be minimized by the early identification and early onset of a prophylactic treatment. The gene discussed is PDCD1; the disease is Autoimmunity.